Symptom severity clusters in myeloproliferative neoplasms are unrelated to disease phenotype: results from a multicenter survey of the East German study group for hematology and oncology (OSHO #97)

Read full text Summarise with VIRAT
Authors: Sabine Felser, Maximilian Koeppel, Rea Kuehl, P le Coutre, Haifa Kathrin Al‐Ali, Susann Schulze, Lars‐Olof Muegge, Julia Bormann, Jan Geissler, Armin Dadgar, Christian Junghanss, Sabina Ulbricht
Cited by: 0
References: 55

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: Myeloproliferative neoplasms (MPNs) comprise a heterogeneous group of clonal hematopoietic stem cell disorders with distinct molecular pathogenesis and treatment strategies. Across all MPN subtypes, patients experience a substantial and persistent symptom burden that impairs health-related quality of life (HrQoL). Because MPNs are typically chronic diseases, lifelong symptom management and supportive therapies play a central role in patient care. Supportive care primarily targets disease- and treatment-related symptoms rather than the underlying malignancy itself. However, it remains unclear whether symptom profiles are comparable across MPN subtypes independent of disease phenotype. Therefore, this analysis aimed to identify symptom severity clusters (SSCs) in a cohort of patients with MPN. Methods: A multicenter cross-sectional survey was conducted. Patients with MPN aged ≥18 years completed questionnaires assessing sociodemographic and disease-specific variables (e.g., sex, age, diagnosis, and current therapies) as well as the severity of 14 symptoms (e.g., fatigue, musculoskeletal pain, and itching), rated on continuous scales ranging from 0 (absent) to 100 (worst imaginable). Hierarchical and K-means cluster analysis as well as multinomial logistic regression were used to identify SSCs and their associations with patient characteristics. Results: The sample comprised 644 patients (63% female; mean age 56.8 ± 13.4 years), including 187 patients with chronic myeloid leukemia, 174 with polycythemia vera, 154 with essential thrombocythemia, and 129 with myelofibrosis. Four SSCs were identified: very high, high, middle, and low symptom severity. Compared with the low SSC, membership in the very high SSC was associated with younger age (95% CI: -0.04 to 0.00) and lower educational level (95% CI: -1.17 to -0.04). Membership in the high SSC was associated with female sex (95% CI: 1.26 to 2.60), higher body mass index (95% CI: 0.00 to 0.11), and lower educational level (95% CI: -1.20 to -0.19). Membership in the very high, high, or middle SSCs, compared with the low SSC, was not associated with diagnostic group. Conclusion: Symptom severity in patients with MPN appears to be comparable across disease subtypes. These findings support a shift toward symptom-focused, multimodal supportive care approaches (e.g., exercise and psychological support) in patients with MPN.

Fields of Study & Subjects

Myeloproliferative Neoplasms: Diagnosis and Treatment Hematological disorders and diagnostics Cancer survivorship and care

Publication details

Journal / source
Frontiers in Oncology
Volume
16
Pages
1802050–1802050
Publication date
23 March 2026
Language
EN